Gemfibrozil, nicotinic acid and combination therapy in patients with isolated hypoalphalipoproteinemia: a randomized, open-label, crossover study. (Q53915752)

From Wikidata

Jump to navigation Jump to search

scientific article

Language	Label	Description	Also known as
English	Gemfibrozil, nicotinic acid and combination therapy in patients with isolated hypoalphalipoproteinemia: a randomized, open-label, crossover study.	scientific article

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

22 May 2018

http://europepmc.org/abstract/MED/10716466

Gemfibrozil, nicotinic acid and combination therapy in patients with isolated hypoalphalipoproteinemia: a randomized, open-label, crossover study. (English)

1 reference

Europe PubMed Central

PubMed publication ID

22 May 2018

http://europepmc.org/abstract/MED/10716466

0 references

hypoalphalipoproteinemia

1 reference

based on heuristic

inferred from title

author name string

Zema MJ

1

1 reference

Europe PubMed Central

PubMed publication ID

22 May 2018

http://europepmc.org/abstract/MED/10716466

language of work or name

0 references

publication date

1 March 2000

1 reference

Europe PubMed Central

PubMed publication ID

22 May 2018

http://europepmc.org/abstract/MED/10716466

Journal of the American College of Cardiology

1 reference

Europe PubMed Central

PubMed publication ID

22 May 2018

http://europepmc.org/abstract/MED/10716466

35

1 reference

Europe PubMed Central

PubMed publication ID

22 May 2018

http://europepmc.org/abstract/MED/10716466

3

1 reference

Europe PubMed Central

PubMed publication ID

22 May 2018

http://europepmc.org/abstract/MED/10716466

640-646

1 reference

Europe PubMed Central

PubMed publication ID

22 May 2018

http://europepmc.org/abstract/MED/10716466

Serum Lipoproteins and Coronary Heart Disease in a Population Study of Hawaii Japanese Men

1 reference

https://api.crossref.org/works/10.1016%2FS0735-1097%2899%2900585-9

7 January 2021

based on heuristic

inferred from DOI database lookup

High density lipoprotein as a protective factor against coronary heart disease. The Framingham Study

1 reference

https://api.crossref.org/works/10.1016%2FS0735-1097%2899%2900585-9

7 January 2021

based on heuristic

inferred from DOI database lookup

The Tromsø heart-study. High-density lipoprotein and coronary heart-disease: a prospective case-control study

1 reference

https://api.crossref.org/works/10.1016%2FS0735-1097%2899%2900585-9

7 January 2021

based on heuristic

inferred from DOI database lookup

High-density lipoprotein cholesterol and cardiovascular disease. Four prospective American studies

1 reference

https://api.crossref.org/works/10.1016%2FS0735-1097%2899%2900585-9

7 January 2021

based on heuristic

inferred from DOI database lookup

High-density lipoprotein cholesterol and coronary heart disease in hypercholesterolemic men: the Lipid Research Clinics Coronary Primary Prevention Trial

1 reference

https://api.crossref.org/works/10.1016%2FS0735-1097%2899%2900585-9

7 January 2021

based on heuristic

inferred from DOI database lookup

Racial differences in high-density lipoprotein cholesterol and coronary heart disease incidence in the usual-care group of the Multiple Risk Factor Intervention Trial

1 reference

https://api.crossref.org/works/10.1016%2FS0735-1097%2899%2900585-9

7 January 2021

based on heuristic

inferred from DOI database lookup

High density lipoprotein cholesterol is not a major risk factor for ischaemic heart disease in British men.

1 reference

https://api.crossref.org/works/10.1016%2FS0735-1097%2899%2900585-9

7 January 2021

based on heuristic

inferred from DOI database lookup

HDL serum cholesterol and 24-year mortality of men in Finland.

1 reference

https://api.crossref.org/works/10.1016%2FS0735-1097%2899%2900585-9

7 January 2021

based on heuristic

inferred from DOI database lookup

High-density lipoprotein cholesterol as a predictor of coronary heart disease risk. The PROCAM experience and pathophysiological implications for reverse cholesterol transport

1 reference

https://api.crossref.org/works/10.1016%2FS0735-1097%2899%2900585-9

7 January 2021

based on heuristic

inferred from DOI database lookup

Serum triglycerides in coronary artery disease

1 reference

https://api.crossref.org/works/10.1016%2FS0735-1097%2899%2900585-9

7 January 2021

based on heuristic

inferred from DOI database lookup

Hyperlipidemia in coronary heart disease. I. Lipid levels in 500 survivors of myocardial infarction.

1 reference

https://api.crossref.org/works/10.1016%2FS0735-1097%2899%2900585-9

7 January 2021

based on heuristic

inferred from DOI database lookup

HDL cholesterol and other lipids in coronary heart disease. The cooperative lipoprotein phenotyping study

1 reference

https://api.crossref.org/works/10.1016%2FS0735-1097%2899%2900585-9

7 January 2021

based on heuristic

inferred from DOI database lookup

Familial lipoprotein disorders in patients with premature coronary artery disease

1 reference

https://api.crossref.org/works/10.1016%2FS0735-1097%2899%2900585-9

7 January 2021

based on heuristic

inferred from DOI database lookup

Lipoprotein cholesterol, apolipoprotein A-I and B and lipoprotein (a) abnormalities in men with premature coronary artery disease.

1 reference

https://api.crossref.org/works/10.1016%2FS0735-1097%2899%2900585-9

7 January 2021

based on heuristic

inferred from DOI database lookup

Dyslipidemias with desirable plasma total cholesterol levels and angiographically demonstrated coronary artery disease

1 reference

https://api.crossref.org/works/10.1016%2FS0735-1097%2899%2900585-9

7 January 2021

based on heuristic

inferred from DOI database lookup

Marked benefit with sustained-release niacin therapy in patients with "isolated" very low levels of high-density lipoprotein cholesterol and coronary artery disease

1 reference

https://api.crossref.org/works/10.1016%2FS0735-1097%2899%2900585-9

7 January 2021

based on heuristic

inferred from DOI database lookup

Effectiveness of low-dose crystalline nicotinic acid in men with low high-density lipoprotein cholesterol levels

1 reference

https://api.crossref.org/works/10.1016%2FS0735-1097%2899%2900585-9

7 January 2021

based on heuristic

inferred from DOI database lookup

Report of the National Cholesterol Education Program Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults. The Expert Panel

1 reference

https://api.crossref.org/works/10.1016%2FS0735-1097%2899%2900585-9

7 January 2021

based on heuristic

inferred from DOI database lookup

Estimating an individual's true cholesterol level and response to intervention.

1 reference

https://api.crossref.org/works/10.1016%2FS0735-1097%2899%2900585-9

7 January 2021

based on heuristic

inferred from DOI database lookup

Effects of therapy with cholestyramine on progression of coronary arteriosclerosis: results of the NHLBI Type II Coronary Intervention Study

1 reference

https://api.crossref.org/works/10.1016%2FS0735-1097%2899%2900585-9

7 January 2021

based on heuristic

inferred from DOI database lookup

Effects of monotherapy with an HMG-CoA reductase inhibitor on the progression of coronary atherosclerosis as assessed by serial quantitative arteriography. The Canadian Coronary Atherosclerosis Intervention Trial.

1 reference

https://api.crossref.org/works/10.1016%2FS0735-1097%2899%2900585-9

7 January 2021

based on heuristic

inferred from DOI database lookup

Effects of lipid lowering by pravastatin on progression and regression of coronary artery disease in symptomatic men with normal to moderately elevated serum cholesterol levels. The Regression Growth Evaluation Statin Study (REGRESS)

1 reference

https://api.crossref.org/works/10.1016%2FS0735-1097%2899%2900585-9

7 January 2021

based on heuristic

inferred from DOI database lookup

The effect of aggressive lowering of low-density lipoprotein cholesterol levels and low-dose anticoagulation on obstructive changes in saphenous-vein coronary-artery bypass grafts

1 reference

https://api.crossref.org/works/10.1016%2FS0735-1097%2899%2900585-9

7 January 2021

based on heuristic

inferred from DOI database lookup

Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia. West of Scotland Coronary Prevention Study Group

1 reference

https://api.crossref.org/works/10.1016%2FS0735-1097%2899%2900585-9

7 January 2021

based on heuristic

inferred from DOI database lookup

The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels. Cholesterol and Recurrent Events Trial investigators

1 reference

https://api.crossref.org/works/10.1016%2FS0735-1097%2899%2900585-9

7 January 2021

based on heuristic

inferred from DOI database lookup

The Lipid Research Clinics Coronary Primary Prevention Trial results. I. Reduction in incidence of coronary heart disease

1 reference

https://api.crossref.org/works/10.1016%2FS0735-1097%2899%2900585-9

7 January 2021

based on heuristic

inferred from DOI database lookup

Prevalence of hyperapobetalipoproteinemia and other lipoprotein phenotypes in men (aged < or = 50 years) and women (< or = 60 years) with coronary artery disease

1 reference

https://api.crossref.org/works/10.1016%2FS0735-1097%2899%2900585-9

7 January 2021

based on heuristic

inferred from DOI database lookup

Cardiovascular disease and multifactorial risk: challenge of the 1980s

1 reference

https://api.crossref.org/works/10.1016%2FS0735-1097%2899%2900585-9

7 January 2021

based on heuristic

inferred from DOI database lookup

Helsinki Heart Study: primary-prevention trial with gemfibrozil in middle-aged men with dyslipidemia. Safety of treatment, changes in risk factors, and incidence of coronary heart disease

1 reference

https://api.crossref.org/works/10.1016%2FS0735-1097%2899%2900585-9

7 January 2021

based on heuristic

inferred from DOI database lookup

Fifteen year mortality in Coronary Drug Project patients: long-term benefit with niacin

1 reference

https://api.crossref.org/works/10.1016%2FS0735-1097%2899%2900585-9

7 January 2021

based on heuristic

inferred from DOI database lookup

Joint effects of serum triglyceride and LDL cholesterol and HDL cholesterol concentrations on coronary heart disease risk in the Helsinki Heart Study. Implications for treatment

1 reference

https://api.crossref.org/works/10.1016%2FS0735-1097%2899%2900585-9

7 January 2021

based on heuristic

inferred from DOI database lookup

Reduction of mortality in the Stockholm Ischaemic Heart Disease Secondary Prevention Study by combined treatment with clofibrate and nicotinic acid

1 reference

https://api.crossref.org/works/10.1016%2FS0735-1097%2899%2900585-9

7 January 2021

based on heuristic

inferred from DOI database lookup

Gemfibrozil for the secondary prevention of coronary heart disease in men with low levels of high-density lipoprotein cholesterol. Veterans Affairs High-Density Lipoprotein Cholesterol Intervention Trial Study Group

1 reference

https://api.crossref.org/works/10.1016%2FS0735-1097%2899%2900585-9

7 January 2021

based on heuristic

inferred from DOI database lookup

Effect of gemfibrozil in men with primary isolated low high-density lipoprotein cholesterol: a randomized, double-blind, placebo-controlled, crossover study.

1 reference

https://api.crossref.org/works/10.1016%2FS0735-1097%2899%2900585-9

7 January 2021

based on heuristic

inferred from DOI database lookup

Comparison of lovastatin and gemfibrozil in normolipidemic patients with hypoalphalipoproteinemia

1 reference

https://api.crossref.org/works/10.1016%2FS0735-1097%2899%2900585-9

7 January 2021

based on heuristic

inferred from DOI database lookup

Gemfibrozil in the treatment of dyslipidaemias in middle-aged male survivors of myocardial infarction

1 reference

https://api.crossref.org/works/10.1016%2FS0735-1097%2899%2900585-9

7 January 2021

based on heuristic

inferred from DOI database lookup

Change in composition of high density lipoprotein during gemfibrozil therapy

1 reference

https://api.crossref.org/works/10.1016%2FS0735-1097%2899%2900585-9

7 January 2021

based on heuristic

inferred from DOI database lookup

Apolipoprotein AI and AII metabolism in patients with primary high-density lipoprotein deficiency associated with familial hypertriglyceridemia

1 reference

https://api.crossref.org/works/10.1016%2FS0735-1097%2899%2900585-9

7 January 2021

based on heuristic

inferred from DOI database lookup

Evaluation of effects of unmodified niacin on fasting and postprandial plasma lipids in normolipidemic men with hypoalphalipoproteinemia.

1 reference

https://api.crossref.org/works/10.1016%2FS0735-1097%2899%2900585-9

7 January 2021

based on heuristic

inferred from DOI database lookup

Low-dose, time-release nicotinic acid: effects in selected patients with low concentrations of high-density lipoprotein cholesterol

1 reference

https://api.crossref.org/works/10.1016%2FS0735-1097%2899%2900585-9

7 January 2021

based on heuristic

inferred from DOI database lookup

New perspectives on the management of low levels of high-density lipoprotein cholesterol

1 reference

https://api.crossref.org/works/10.1016%2FS0735-1097%2899%2900585-9

7 January 2021

based on heuristic

inferred from DOI database lookup

Rationale and design of a secondary prevention trial of increasing serum high-density lipoprotein cholesterol and reducing triglycerides in patients with clinically manifest atherosclerotic heart disease (the Bezafibrate Infarction Prevention Trial)

1 reference

https://api.crossref.org/works/10.1016%2FS0735-1097%2899%2900585-9

7 January 2021

based on heuristic

inferred from DOI database lookup

Management of primary hyperlipidemia

1 reference

https://api.crossref.org/works/10.1016%2FS0735-1097%2899%2900585-9

7 January 2021

based on heuristic

inferred from DOI database lookup

Prognostic and therapeutic significance of low levels of high-density lipoprotein cholesterol: current perspectives

1 reference

https://api.crossref.org/works/10.1016%2FS0735-1097%2899%2900585-9

7 January 2021

based on heuristic

inferred from DOI database lookup

Identifiers

10.1016/S0735-1097(99)00585-9

1 reference

Europe PubMed Central

PubMed publication ID

22 May 2018

http://europepmc.org/abstract/MED/10716466

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

22 May 2018

http://europepmc.org/abstract/MED/10716466

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q53915752&oldid=1613308207"